In a strategic collaboration, Glenmark Pharmaceuticals and Ichnos Sciences have officially launched Ichnos Glenmark Innovation (IGI), a groundbreaking alliance aimed at expediting new drug discovery in the field of cancer treatment.

IGI harnesses the combined research and development expertise of Glenmark in small molecules and Ichnos in novel biologics, forging a powerful partnership to advance cutting-edge therapy solutions for hematological malignancies and solid tumors.

The newly established IGI boasts a robust pipeline featuring three innovative oncology molecules currently undergoing clinical trials, targeting multiple myeloma, acute myeloid leukemia, and solid tumors.

Notably, two of these molecules have received orphan drug designation from the U.S. FDA. Additionally, IGI holds two autoimmune disease assets that have been licensed to prominent companies.

The collaborative effort will leverage the strengths of three global innovation centers: Ichnos' clinical development-focused headquarters in New York City, NY, USA; the biologics research center in Lausanne, Switzerland; and Glenmark's small molecule research center at Mahape in Mumbai, India.

This alliance signifies a significant stride towards advancing cancer treatment research, with IGI poised to play a pivotal role in delivering innovative and impactful therapeutic solutions.